Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Pfizer gets U.S. approval for $225,000 a year heart drug

The U.S. Food and Drug Administration approved Pfizer Inc.’s oral drug tafamidis to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy.

Read More »

Teva migraine drug helps to contain profit fall

Teva Pharmaceutical Industries posted a slightly smaller than expected drop in first-quarter 2019 profit and forecast a sharp rise in 2020 revenue from the company’s new migraine drug Ajovy.

Read More »

Gates, Bezos team up to fund Alzheimer’s diagnostics

The Bill & Melinda Gates Foundation and Jeff Bezos’ Day One Fund teamed up to donate $15 million to the Diagnostics Accelerator as part of the Alzheimer’s Drug Discovery Foundation.

Read More »

Exclusive: Sweden’s Lobsor Gains U.S. Patent for Advanced Parkinson’s Disease Treatment

Privately held Swedish pharmaceutical company Lobsor Pharmaceuticals AB is eying the U.S. market for a potential treatment for neurodegenerative diseases such as Parkinson’s disease.

Read More »

Great-grandparents or cousins with Alzheimer’s linked to higher risk for the disease

Having second-degree or third-degree relatives with Alzheimer’s raises a person’s risk of developing the disease, a new study suggests.

Read More »

Parkinson’s drug trial offers glimmer of hope for brain cells

An experimental drug could offer hope for restoring damaged brain cells in Parkinson’s patients, scientists said on Wednesday, although they cautioned that a clinical trial was not able to prove the treatment slowed or halted the neurodegenerative disease.

Read More »

Voyager and AbbVie Forge Another Neurodegenerative Therapy Collaboration Worth More Than $1 Billion

Voyager Therapeutics struck a deal with AbbVie to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson’s disease and other diseases characterized by the abnormal accumulation of misfolded alpha-synuclein protein.

Read More »

Teva Pharmaceutical sees weaker than expected 2019

Teva Pharmaceutical Industries forecast lower revenue and profit for 2019, missing analysts’ expectations, as the company faces generic competition for two key branded drugs.

Read More »

Roche, AC Immune drop Alzheimer’s drug trials

Roche Holding and partner AC Immune called a halt to two late-stage studies of the companies’ crenezumab drug for early Alzheimer’s, the latest in a string of failures to find a treatment for the progressive brain disease.

Read More »

A Link Between Gum Disease and Alzheimer’s?

Researchers with Cortexyme published research in the journal Science Advances describing the role of Porphyromonas gingivalis, a bacteria that causes gingivitis, to Alzheimer’s disease.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom